Curasight A/S (CPH: CURAS) announced that its Phase 1 clinical trial investigating uTREAT in glioblastoma patients is now open for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE